Demand for medical testing services is rising.

July 23 (Reuters) - Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates. Shares of the ​New ...

As Cyclospora cases reach record levels this summer, Quest Diagnostics is seeing increased demand for testing. WRAL takes a ...

"We now expect revenues to be between $11.95 billion and $12.05 billion... Reported EPS to be in a range of $9.97 to $10.17 and adjusted EPS in a range of $11.05 to $11.25." (Executive VP & CFO Samad) ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the ...

Quest Diagnostics Inc. closed 2.50% below its 52-week high of $237.78, which the company achieved on July 23rd.

Despite being one of the most common substances found in drug screenings, reporting from The Wall Street Journal noted a decline in the number of employers that continue to screen for cannabis use.